CIRCULATING ANTIBODIES TO ERYTHROPOIETIN ARE ASSOCIATED WITH LOWER EFFICACY OF RECOMBINANT EPOETIN TREATMENT IN PATIENTS UNDERGOING HAEMODIALYSIS
Biological preparations (BP) obtained by gene engineering possess a special characteristic called immunogenicity, i.e. propensity of biological drugs to induce an undesired immune response associated with arising anti-drug antibodies. These antibodies can change BP pharmacokinetics and pharmacodynam...
Guardado en:
Autores principales: | V. D. Nazarov, S. V. Lapin, V. A. Dobronravov, K. A. Smirnov, D. A. Mayer, T. O. Muzhetskaya, A. A. Totolian |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
SPb RAACI
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/404653d3121049a18d24b7924dea3d80 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Characteristics of erythropoietin antibodies in patients treated with recombinant human erythropoietin
por: A. M. Kudryashova, et al.
Publicado: (2020) -
Detection of antibodies to erythropoietin-based drugs: is it possible to create the universal test system?
por: A. M. Kudryashova, et al.
Publicado: (2021) -
EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS
por: Muhammad Sajid Hussain, et al.
Publicado: (2021) -
The use of erythropoietins in oncology
por: Liliya E. Ziganshina, et al.
Publicado: (2021) -
Serum Erythropoietin level in children with different degrees of chronic renal failure
por: Gh Al-Hosseini Hashemi, et al.
Publicado: (2000)